Eli Lilly
Regulatory Tracker: Lilly’s Retevmo Secures Pediatric Cancer FDA Nod ###
Retevmo, Eli Lilly, FDA approval, pediatric cancer, RET-altered, thyroid cancer, solid tumors, accelerated approval, LIBRETTO-121 trial, selpercatinib
Lilly Expands Radiopharmaceutical Portfolio with Aktis Acquisition
Lilly, Aktis, radiopharmaceutical, acquisition, portfolio, cancer therapy, targeted treatment
Lilly’s Weekly Insulin Therapy Excels in Two Major Clinical Trials, Narrowing Gap with Novo Nordisk
Lilly, Novo Nordisk, weekly insulin, primary endpoint, pivotal trials, diabetes management, insulin therapy, clinical trials, diabetes treatment, pharmaceutical industry.
Lilly-backed Lycia Therapeutics Secures $106M for Clinical Trials on Lysosomal Protein Degraders
Lycia Therapeutics, Eli Lilly, lysosomal protein degraders, clinical trials, funding, biotechnology, drug development
Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management
Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.
FDA to Review Lilly’s Alzheimer’s Drug Donanemab in June Advisory Committee Meeting
FDA, Lilly, Alzheimer’s, donanemab, June, AdCom, review, approval, treatment, neurodegenerative disease.
Lilly’s Future Brightens with Increased Visibility on Mounjaro and Zepbound Production Capacity
Lilly, Mounjaro, Zepbound, production capacity, financial outlook, pharmaceutical industry, drug manufacturing.
Lilly Acquires Injectable Medicines Production Facility from Nexus Pharma
Lilly, Nexus Pharma, injectable medicines, facility acquisition, pharmaceutical manufacturing, strategic expansion, production capacity.
Eli Lilly Expands Manufacturing Capacity with Nexus Plant Acquisition Amid Ongoing Mounjaro and Zepbound Supply Challenges
Eli Lilly, Nexus manufacturing plant, Wisconsin, Mounjaro, Zepbound, drug shortages, manufacturing capacity, pharmaceutical industry, acquisition
Eli Lilly Anticipates Zepbound Label Expansion Following Positive Phase III Sleep Apnea Study Results
Eli Lilly, Zepbound (tirzepatide), Phase III Sleep Apnea Study, SURMOUNT-OSA, Obstructive Sleep Apnea (OSA), Label Expansion, Fast Track Designation, Symptom Improvement